Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.

Trial Details

NCT ID
NCT06980116
Phase
PHASE1
Sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Status
RECRUITING
Cancer Type
Marginal Zone Lymphoma Lymphoma
Interventions
  • EXS73565
Locations (sample)
  • Tbilisi, Georgia|41.69143,44.83412
  • Athens, Greece|37.98376,23.72784
  • Pátrai, Greece|38.2462,21.73508
  • Thessaloniki, Greece|40.64072,22.93493
  • Chisinau, Moldova|47.00902,28.85938

Key Eligibility Criteria

  • Age ≥18 years at the time of signing the informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformat…
  • Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Marginal Zone Lymphoma Lymphoma Trials on Trialify →